邹滔滔

男， 中山大学， 教授/研究员/教授级高工或同等级别

学习/工作经历

2006.09—2010.06 武汉大学 化学与分子科学学院 本科
2010.09—2015.02 香港大学 化学系 博士
2015.02—2018.02 华威大学、香港大学、Scripps研究所 博士后
2018.03—2018.07 香港中文大学（深圳） 理工学院 助理教授
2018.07至今 中山大学 药学院 教授

研究领域和兴趣

药物化学生物学、生物无机化学

主要业绩

邹滔滔，博士，中山大学教授、博士生导师，国家优秀青年基金获得者，广东省“珠江人才计划”青年拔尖人才，中山大学“百人计划”中青年杰出人才。本科毕业于武汉大学化学学院（导师：杨楚罗教授），博士毕业于香港大学化学系（导师：支志明院士），并在Scripps研究所（导师：Xiang-Lei Yang教授、Paul Schimmel教授)、香港大学（导师：支志明教授）、华威大学（导师Peter J Sadler教授）从事博士后研究工作，研究方向为药物化学生物学和生物无机化学，长期致力于开发含金属药物，近期研究方向集中在设计新型抗癌前体药物和发展具有抗癌免疫活性的小分子药物等领域，并以通讯作者在Nat. Rev. Chem., Acc. Chem. Res., J. Am. Chem. Soc., Angew. Chem. Int. Ed.等期刊发表多篇论文。现担任《Science Bulletin》和《科学通报》特邀编委。

代表成果

1. Liu, M.†; Xiong, X.†; Zhang, A.*; Zou, T.* "Subcellular photochemistry for precision spatial protein targeting". Nat. Rev. Chem. 2026, https://doi.org/10.1038/s41570-026-00864-1.
2. Zhong, Z.†; Liu, H.†; Wu, Q.†; Cao, B.†; Peng, Y.; Liu, M.; Yang, L.-M.; Lin, Y.; Huang, K.-B.*; Xiong, X.*; Shang, J.*; Zou, T.* "Beyond Thiol-Enzyme Inhibition: Sterically Bulky NHC-Au(I) Complexes are Catalytically Active Anticancer Agents with Reprogrammed Immunomodulatory Function". J. Am. Chem. Soc. 2026, 148, 8511-8523.
3. Wang, Y.†; Cao, B.†; Wang, Q.†; Zhong, S.; Fang, X.; Wang, J.*; Chan, A. S. C.; Xiong, X.*; Zou, T.* "Ligand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation", Nat. Commun. 2025, 16, 7347.
4. Liu, M.; Liu, H.; Yang, Y.; Xiong, X.*; Zou, T.* "Subcellular Photocatalysis Enables Tumor-Targeted Inhibition of Thioredoxin Reductase I by Organogold(I) Complexes", J. Am. Chem. Soc. 2025, 147, 15719-15731.
5. Xie, Z.†; Cao, B.†; Zhao,†; Liu, M.†; Lao, Y.; Luo, H.; Zhong, Z.; Xiong, X.; Wei, W.*; Zou, T.* "Ion Pairing Enables Targeted Prodrug Activation via Red Light Photocatalysis: A Proof-of-Concept Study with Anticancer Gold Complexes." J. Am. Chem. Soc. 2024, 146, 8547-8556.
6. Liu, M.; Luo, Y.; Yan, J.; Xiong, X.; Xing, X.*; Kim, J. S.*; Zou, T.* "Photoactivation of Boronic Acid Prodrugs via a Phenyl Radical Mechanism: Iridium(III) Anticancer Complex as an Example." J. Am. Chem. Soc. 2023, 145, 10082-10091.
7. Jiang, J.†; Xiong, X.†; Zou, T.* "Modulating the Chemical Reactivity of Gold Complexes in Living Systems: From Concept to Biomedical Applications." Acc. Chem. Res. 2023, 56, 1043-1056.
8. Luo, Y.; Cao, B.; Zhong, M.; Liu, M.; Xiong, X.; Zou, T.*, "Organogold(III) Complexes Display Conditional Photoactivities: Evolving From Photodynamic into Photoactivated Chemotherapy in Response to O2 Consumption for Robust Cancer Therapy." Angew. Chem. Int. Ed. 2022, 61 e202212689.
9. Xiong, X.†; Huang, K.-B.†; Wang, Y.†; Cao, B.; Luo, Y.; Chen, H.; Yang, Y.; Long, Y.; Liu, M.; Chan, A. S. C.; Liang, H.*; Zou, T.*, "Target Profiling of an Iridium(III)-based Immunogenic Cell Death Inducer Unveils the Engagement of Unfolded Protein Response Regulator BiP." J. Am. Chem. Soc. 2022, 144, 10407-10416.
10. Jiang, J.†; Cao, B.†; Chen, Y.†; Luo, H.; Xue, J.; Xiong, X.; Zou, T.*, "Alkylgold(III) Complexes Undergo Unprecedented Photo-Induced β-Hydride Elimination and Reduction for Targeted Cancer Therapy."Angew. Chem. Int. Ed. 2022, 61, e202201103.
11. Long, Y.†; Cao, B.†; Xiong, X.; Chan, A. S. C.; Sun, R. W.-Y.; Zou, T.*, "Bioorthogonal Activation of Dual Catalytic and Anti-Cancer Activities of Organogold(I) Complexes in Living Systems." Angew. Chem. Int. Ed. 2021, 60, 4133-4141. (Hot Paper)
12. Luo, H.; Cao, B.; Chan, A. S. C.; Sun, R. W.-Y.; Zou, T.*, "Cyclometalated Gold(III)-Hydride Complexes Exhibit Visible Light-Induced Thiol Reactivity and Act as Potent Photo-Activated Anti-Cancer Agents." Angew. Chem. Int. Ed. 2020, 59, 11046-11052.

*以上信息由高级会员个人更新和维护。